A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate… (NCT07641855) | Clinical Trial Compass
Not Yet RecruitingPhase 2/3
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
China180 participantsStarted 2026-06
Plain-language summary
This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Voluntarily join this study and sign the informed consent form;
. Meet the definition of mCRPC according to PCWG3 criteria;
. Agree to provide archived tumor tissue specimens from primary or metastatic lesions within 3 years or fresh tissue samples;
. Meet the evaluable lesion requirement defined by any one of the following assessment criteria;
. ECOG performance status score of 0 or 1;
Exclusion criteria
. Patients with metastatic castration-resistant prostate cancer who are suitable for radical local therapy;
. Patients with non-prostatic acinar adenocarcinoma confirmed by histopathology or cytology, among others;
. Patients who have previously received antibody-drug conjugates using topoisomerase I inhibitors as the toxin, among others;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1BL-B01D1 is still in a Phase 2/3 trial that hasn't started recruiting yet — given where I am in my treatment right now, would it make more sense to try an already-approved therapy for my metastatic castration-resistant prostate cancer first, rather than waiting for this study to open?
2Since this trial is measuring progression-free survival as its main goal, what does that actually mean for my situation — does slowing how fast the cancer grows translate into a meaningful difference in how I'll feel day to day?
3BL-B01D1 is being tested as a combination therapy — do you know yet what it's being combined with, and are there specific side effects from that combination I should understand before deciding whether this is worth considering?
4Because the trial isn't recruiting yet, there's no timeline I can count on — how would delaying treatment to wait for this study affect my current prognosis compared to starting something available now?
5Are there other ongoing or open trials for metastatic castration-resistant prostate cancer that are already enrolling that might be worth comparing against this one, so we can weigh all the options together?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.